Segment Information

9 Months Ended

Sep. 30, 2019

Segment Information

Segment Information

13. Segment Information

Prior to the merger with Napo, the Company managed its operations as a single segment for the purposes of assessing performance and making operating decisions. The Company reorganized its segments to reflect the change in the organizational structure resulting from the merger with Napo. Post-merger, the Company manages its operations through two reportable segments—human health and animal health. The human health segment is focused on developing and commercializing human products and the ongoing commercialization of Mytesi™, which is approved by the U.S. FDA for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. The animal health segment is focused on developing and commercializing prescription and non-prescription products for companion and production animals.

The Company's reportable segments net revenues and net loss for the three and nine months ended September 30, 2019 and 2018 consisted of:

	Three Months Ended				Nine Months Ended
	September 30,				September 30,
	2019		2018		2019		2018
	(unaudited)				(unaudited)
Revenue from external customers
Human Health	$	957,059	$	1,107,682	$	4,184,912	$	2,545,121
Animal Health		15,720		24,385		83,294		275,148
Consolidated Totals	$	972,779	$	1,132,067	$	4,268,206	$	2,820,269
Segment profit (loss)
Human Health	$	(3,955,115)	$	(3,145,782)	$	(16,585,956)	$	(10,519,413)
Animal Health		(3,599,950)		(2,992,570)		(15,994,097)		(8,972,759)
Consolidated Totals	$	(7,555,065)	$	(6,138,352)	$	(32,580,053)	$	(19,492,172)

The Company's reportable segments assets consisted of the following:

		September 30,		December 31,
	2019		2018
Segment assets
Human Health	$	33,571,477	$	37,985,935
Animal Health		64,797,329		54,893,593
Total	$	98,368,806	$	92,879,528
The reconciliation of segments assets to the consolidated assets is as follows:
		September 30,		December 31,
	2019		2018
Total assets for reportable segments		98,368,806		92,879,528
Less: Investment in subsidiary		(29,240,965)		(29,240,965)
Less: Intercompany loan		(33,501,296)		(22,596,618)
Consolidated Totals	$	35,626,544	$	41,041,945